Melola Discovery

← Melola Discovery

Akses terbuka Jurnal Tanpa peringkat SINTA

Monitoring Kidney Function Through the Use of Candesartan, Telmisartan or Valsartan Antihypertensive Therapy towards Patients CKD

Media Kesehatan Masyarakat Indonesia · Vol. 18 No. 1 (2022) · hlm. 1–9

DOI
10.30597/mkmi.v18i1.17780
ISSN
2356-4067, 0216-2482
Terbit
2022-03-31
Penerbit
Faculty of Public Health, Hasanuddin University, Makassar
Bahasa
en
Lisensi
creativecommons.org/licenses/by-nc-sa/4.0/

Abstrak

Chronic Kidney Disease (CKD) lower kidney function caused by an irreversible reduction in normal nephron function. Globally, CKD contributes to the cause of death. Activation of the Renin-Angiotensin-Aldosterone system is involved in the pathogenesis. ARBs have a cardiorenal protective effect. The purpose of this study was to determine the changes in kidney function with the use of Candesartan, Telmisartan or Valsartan antihypertensive therapies in CKD patients. This research method was a prospective observational cohort study looking at changes in kidney function (BUN and Serum Creatinine) at 1 and 6 months of using Antihypertensive Drugs Valsartan, Telmisartan, and Candesartan and tested by statistical analysis. The number of samples in this study was 72 patients which are 24 patients (Candesartan), 27 patients (Telmisartan), and 21 patients (Valsartan). The results showed that the Candesartan group experienced a decrease in average BUN of 0.13±0.85 mg/dl and serum creatinine of 0.004±0.09 mg/dl with independent t-test p=0.479 (p>0.05), Serum Creatinine p= 0.809 (p>0.05). The Telmisartan group experienced a decrease in average BUN of 4.74±5.16 mg/dl and serum creatinine of 0.33±0.20 mg/dl with Wilcoxon BUN test results p=0.000 (p<0.05), Serum Creatinine p=0.000 (p<0.05). In contrast, in the valsartan group, there was no change. So, it can be said that telmisartan has the highest effectiveness in kidney function (BUN and Serum Creatinine).

Kata kunci

Jaringan kolaborasi para penulis

13 penulis · 51 tautan kepenulisan bersama · 32 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Universitas Airlangga
  • Akademi Farmasi Surabaya
  • Universitas Nahdlatul Ulama Surabaya
  • Universitas Muhammadiyah Lamongan
  • University of Malaya
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Lilik HerawatiUniversitas Airlangga1
Mohammad Fathul QoribUniversitas Airlangga1
Muhammad Fath Alhaqqi Sanis SalamyUniversitas Airlangga1
Izzul MujahidinUniversitas Airlangga1
Salamun SalamunUniversitas Airlangga1
Ahmed Zaiyan Nahel SalamyUniversitas Airlangga1
Achmad Yarziq Mubarak Salis SalamyUniversitas Nahdlatul Ulama Surabaya1
Moh Nahar Azmi MohamedUniversity of Malaya1
Ain Darojah Siddiq Ramadhan RamadhanUniversitas Nahdlatul Ulama Surabaya1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) https://journal.unhas.ac.id/index.php/mkmi/oai, pertama di-harvest 5 Nov 2026, terakhir terlihat 15 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Monitoring Kidney Function Through the Use of Candesartan, Telmisartan or Valsartan Antihypertensive Therapy towards Patients CKD</dc:title>
	<dc:creator xml:lang="en">Fandinata, Selly Septi</dc:creator>
	<dc:creator xml:lang="en">Darmawan, Rizky </dc:creator>
	<dc:creator xml:lang="en">Utami, Primanitha Ria </dc:creator>
	<dc:creator xml:lang="en">Ulfa, Ninik Mas </dc:creator>
	<dc:subject xml:lang="en">CKD</dc:subject>
	<dc:subject xml:lang="en">ARBs</dc:subject>
	<dc:subject xml:lang="en">Telmisartan</dc:subject>
	<dc:description xml:lang="en">Chronic Kidney Disease (CKD) lower kidney function caused by an irreversible reduction in normal nephron function. Globally, CKD contributes to the cause of death. Activation of the Renin-Angiotensin-Aldosterone system is involved in the pathogenesis. ARBs have a cardiorenal protective effect. The purpose of this study was to determine the changes in kidney function with the use of Candesartan, Telmisartan or Valsartan antihypertensive therapies in CKD patients. This research method was a prospective observational cohort study looking at changes in kidney function (BUN and Serum Creatinine) at 1 and 6 months of using Antihypertensive Drugs Valsartan, Telmisartan, and Candesartan and tested by statistical analysis. The number of samples in this study was 72 patients which are 24 patients (Candesartan), 27 patients (Telmisartan), and 21 patients (Valsartan). The results showed that the Candesartan group experienced a decrease in average BUN of 0.13±0.85 mg/dl and serum creatinine of 0.004±0.09 mg/dl with independent t-test p=0.479 (p&amp;gt;0.05), Serum Creatinine p= 0.809 (p&amp;gt;0.05). The Telmisartan group experienced a decrease in average BUN of 4.74±5.16 mg/dl and serum creatinine of 0.33±0.20 mg/dl with Wilcoxon BUN test results p=0.000 (p&amp;lt;0.05), Serum Creatinine p=0.000 (p&amp;lt;0.05). In contrast, in the valsartan group, there was no change. So, it can be said that telmisartan has the highest effectiveness in kidney function (BUN and Serum Creatinine).</dc:description>
	<dc:publisher xml:lang="en">Faculty of Public Health, Hasanuddin University, Makassar</dc:publisher>
	<dc:date>2022-03-31</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://journal.unhas.ac.id/index.php/mkmi/article/view/17780</dc:identifier>
	<dc:identifier>10.30597/mkmi.v18i1.17780</dc:identifier>
	<dc:source xml:lang="en">Media Kesehatan Masyarakat Indonesia; Vol. 18 No. 1: MARCH 2022; 1-9</dc:source>
	<dc:source>2356-4067</dc:source>
	<dc:source>0216-2482</dc:source>
	<dc:source>10.30597/mkmi.v18i1</dc:source>
	<dc:language>en</dc:language>
	<dc:relation>https://journal.unhas.ac.id/index.php/mkmi/article/view/17780/8533</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2022 By author</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc-sa/4.0/</dc:rights>
</oai_dc:dc>